Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.

Kamat AM, Lerner SP, O'Donnell M, Georgieva MV, Yang M, Inman BA, Kassouf W, Boorjian SA, Tyson MD, Kulkarni GS, Chang SS, Konety BR, Svatek RS, Balar A, Witjes JA.

Eur Urol Oncol. 2020 Mar 19. pii: S2588-9311(20)30031-6. doi: 10.1016/j.euo.2020.02.006. [Epub ahead of print] Review.

PMID:
32201133
2.

Converging Roads to Early Bladder Cancer.

Necchi A, Gallina A, Dyrskjøt L, Roupret M, Kamat AM, Spiess PE, Grivas P, Gibb EA, Briganti A, Montorsi F.

Eur Urol. 2020 Mar 17. pii: S0302-2838(20)30141-X. doi: 10.1016/j.eururo.2020.02.031. [Epub ahead of print] No abstract available.

PMID:
32197887
3.

Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer.

Mostafid H, Babjuk M, Bochner B, Lerner SP, Witjes F, Palou J, Roupret M, Shariat S, Gontero P, van Rhijn B, Zigeuner R, Sylvester R, Comperat E, Burger M, Malavaud B, Soloway M, Williams S, Black P, Daneshmand S, Steinberg G, Brausi M, Catto J, Kamat AM.

Eur Urol. 2020 Mar 16. pii: S0302-2838(20)30146-9. doi: 10.1016/j.eururo.2020.03.005. [Epub ahead of print]

PMID:
32192815
4.

KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC.

Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, Shariat S, Nam K, Kapadia E, Frenkl T, Steinberg G.

Future Oncol. 2020 Apr;16(10):507-516. doi: 10.2217/fon-2019-0817. Epub 2020 Mar 12.

5.

Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.

Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM.

Eur Urol. 2020 Mar 3. pii: S0302-2838(20)30118-4. doi: 10.1016/j.eururo.2020.02.012. [Epub ahead of print]

PMID:
32143924
6.

Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes.

Narayan VM, Seif MA, Lim AH, Li R, Matulay JT, Kukreja JB, Qiao W, Hwang H, Shah JB, Pisters L, Kamat AM, Dinney C, Navai N.

Urol Oncol. 2020 Jan 14. pii: S1078-1439(19)30492-2. doi: 10.1016/j.urolonc.2019.12.005. [Epub ahead of print]

PMID:
31953001
7.

Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG).

Matulay JT, Soloway M, Witjes JA, Buckley R, Persad R, Lamm DL, Boehle A, Palou J, Colombel M, Brausi M, Kamat AM.

BJU Int. 2020 Jan 16. doi: 10.1111/bju.14995. [Epub ahead of print] Review.

PMID:
31950596
8.

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.

Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MA, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA.

J Urol. 2019 Dec 10:101097JU0000000000000688. doi: 10.1097/JU.0000000000000688. [Epub ahead of print]

PMID:
31821066
9.

Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 2020;77:420-33: A Statement from the International Bladder Cancer Network.

Williams SB, Black PC, Dyrskjøt L, Seiler R, Schmitz-Dräger B, Nawroth R, Todenhöfer T, Kamat AM, Goebell PJ.

Eur Urol. 2020 Apr;77(4):e105-e106. doi: 10.1016/j.eururo.2019.11.011. Epub 2019 Nov 29. No abstract available.

PMID:
31787429
10.

Predictors of Response to Intravesical Therapy.

Li R, Kamat AM.

Urol Clin North Am. 2020 Feb;47(1):23-33. doi: 10.1016/j.ucl.2019.09.005. Review.

PMID:
31757297
11.

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees.

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.

Eur Urol. 2020 Feb;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Epub 2019 Nov 19.

PMID:
31753752
12.

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Vives Rivera FA, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA.

Ann Oncol. 2019 Nov 1;30(11):1697-1727. doi: 10.1093/annonc/mdz296.

PMID:
31740927
13.

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ.

Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11.

PMID:
31712383
14.

Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.

Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S.

JAMA Oncol. 2019 Oct 31:1-9. doi: 10.1001/jamaoncol.2019.4114. [Epub ahead of print]

PMID:
31670753
15.

A Case for Risk-adapted Management of Low-grade Bladder Tumors.

Soloway M, Matulay JT, Kamat AM.

Eur Urol Oncol. 2020 Feb;3(1):128-129. doi: 10.1016/j.euo.2019.09.007. Epub 2019 Oct 20.

PMID:
31645295
16.
17.

What Is the Significance of Variant Histology in Urothelial Carcinoma?

Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA 3rd, Roupret M, Kamat AM.

Eur Urol Focus. 2019 Sep 15. pii: S2405-4569(19)30278-0. doi: 10.1016/j.euf.2019.09.003. [Epub ahead of print] Review.

PMID:
31530497
18.

Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails.

Moschini M, Shariat SF, Black P, Kamat AM, Stabile A, Cathelineau X, Kassouf W, Bochner BH, Xylinas E, Roupret M, Boorjian SA, Catto JW, Sanchez-Salas R.

Eur Urol. 2020 Jan;77(1):1-2. doi: 10.1016/j.eururo.2019.08.021. Epub 2019 Sep 8.

PMID:
31506227
19.

Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.

Huo J, Ray-Zack MD, Shan Y, Chamie K, Boorjian SA, Kerr P, Jana B, Freedland SJ, Kamat AM, Mehta HB, Williams SB.

Eur Urol Oncol. 2019 Sep;2(5):497-504. doi: 10.1016/j.euo.2018.07.009. Epub 2018 Aug 17.

PMID:
31411998
20.

Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?

Burger M, Kamat AM, McConkey D.

Eur Urol Oncol. 2019 Aug 6. pii: S2588-9311(19)30093-8. doi: 10.1016/j.euo.2019.06.012. [Epub ahead of print]

21.

Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series.

Seiler R, Black PC, Williams SB, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ.

Urol Oncol. 2019 Nov;37(11):815-817. doi: 10.1016/j.urolonc.2019.06.025. Epub 2019 Jul 31. Review. No abstract available.

PMID:
31377169
22.

How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin?

Kamat AM, Gontero P, Palou J.

Eur Urol Oncol. 2019 Jul 12. pii: S2588-9311(19)30094-X. doi: 10.1016/j.euo.2019.06.013. [Epub ahead of print]

23.

Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies.

Pignot G, Loriot Y, Kamat AM, Shariat SF, Plimack ER.

Eur Urol Oncol. 2019 Jul;2(4):355-364. doi: 10.1016/j.euo.2019.01.002. Epub 2019 Jan 31. Review.

PMID:
31277773
24.

Bioinspired Cilia Sensors with Graphene Sensing Elements Fabricated Using 3D Printing and Casting.

Kamat AM, Pei Y, Kottapalli AGP.

Nanomaterials (Basel). 2019 Jun 30;9(7). pii: E954. doi: 10.3390/nano9070954.

25.

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM.

Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10.

PMID:
31200843
26.

Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.

Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB.

JAMA Surg. 2019 Jun 5:e191629. doi: 10.1001/jamasurg.2019.1629. [Epub ahead of print]

PMID:
31166593
27.

Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.

Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC.

Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15. Review.

PMID:
31102625
28.

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM.

Eur Urol Oncol. 2018 Aug;1(3):190-198. doi: 10.1016/j.euo.2018.05.002. Epub 2018 May 30.

PMID:
31102620
29.

Welcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers.

Briganti A, Albiges L, Giannarini G, Kamat AM, Nguyen PL.

Eur Urol Oncol. 2018 May;1(1):1-2. doi: 10.1016/j.euo.2018.04.002. Epub 2018 May 15. No abstract available.

PMID:
31100222
30.

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts.

Maulhardt HA, Hylle L, Frost MV, Tornio A, Dafoe S, Drummond L, Quinn DI, Kamat AM, diZerega GS.

Cancers (Basel). 2019 Apr 24;11(4). pii: E577. doi: 10.3390/cancers11040577.

31.

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.

Nat Rev Urol. 2019 Jun;16(6):377-386. doi: 10.1038/s41585-019-0184-4. Review.

PMID:
31019310
32.

Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer.

Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL.

Eur Urol Oncol. 2019 Mar;2(2):119-125. doi: 10.1016/j.euo.2018.07.006. Epub 2018 Aug 14.

PMID:
31017086
33.

Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study.

Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM.

Future Oncol. 2019 Apr;15(12):1323-1334. doi: 10.2217/fon-2018-0654. Epub 2019 Apr 3.

PMID:
30942088
34.

The role of metastatic burden in cytoreductive/consolidative radical cystectomy.

Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N.

World J Urol. 2019 Dec;37(12):2691-2698. doi: 10.1007/s00345-019-02693-y. Epub 2019 Mar 12.

PMID:
30864005
35.

New horizons in bladder cancer research.

Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ.

Urol Oncol. 2019 Mar 7. pii: S1078-1439(18)30508-8. doi: 10.1016/j.urolonc.2018.12.014. [Epub ahead of print] Review.

PMID:
30852032
36.

Clinical and Genomic Considerations for Variant Histology in Bladder Cancer.

Matulay JT, Narayan VM, Kamat AM.

Curr Oncol Rep. 2019 Feb 26;21(3):23. doi: 10.1007/s11912-019-0772-8. Review.

PMID:
30806832
37.

The impact of squamous histology on survival in patients with muscle-invasive bladder cancer.

Matulay JT, Woldu SL, Lim A, Narayan VM, Li G, Kamat AM, Anderson CB.

Urol Oncol. 2019 Jun;37(6):353.e17-353.e24. doi: 10.1016/j.urolonc.2019.01.020. Epub 2019 Jan 28.

PMID:
30704959
38.

Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series1.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ.

Urol Oncol. 2019 Jan 22. pii: S1078-1439(19)30003-1. doi: 10.1016/j.urolonc.2019.01.003. [Epub ahead of print] Review.

PMID:
30683454
39.

Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.

Peyton CC, Chipollini J, Azizi M, Kamat AM, Gilbert SM, Spiess PE.

World J Urol. 2019 Oct;37(10):2017-2029. doi: 10.1007/s00345-018-2591-1. Epub 2018 Dec 7. Review.

PMID:
30535583
40.

Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer-Reply.

Williams SB, Kamat AM, Mehta HB.

JAMA Surg. 2019 Feb 1;154(2):186. doi: 10.1001/jamasurg.2018.4372. No abstract available.

PMID:
30476959
41.

Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model.

Ray-Zack MD, Shan Y, Mehta HB, Yu X, Kamat AM, Williams SB.

Urol Oncol. 2019 Nov;37(11):837-843. doi: 10.1016/j.urolonc.2018.10.024. Epub 2018 Nov 13. Review.

PMID:
30446462
42.

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN.

Eur Urol Oncol. 2018 Jun;1(2):91-100. doi: 10.1016/j.euo.2018.03.005. Epub 2018 Jun 6.

43.

Current Use and Promise of Urinary Markers for Urothelial Cancer.

Tabayoyong W, Kamat AM.

Curr Urol Rep. 2018 Oct 17;19(12):96. doi: 10.1007/s11934-018-0857-1. Review.

PMID:
30328534
44.

Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.

Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM.

Eur Urol. 2019 Jan;75(1):8-10. doi: 10.1016/j.eururo.2018.09.028. Epub 2018 Oct 6.

PMID:
30301695
45.

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.

Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF.

Eur Urol. 2018 Dec;74(6):784-795. doi: 10.1016/j.eururo.2018.09.001. Epub 2018 Sep 26.

46.

Editorial comment.

Kamat AM, Gontero P.

Curr Opin Urol. 2018 Nov;28(6):555-556. doi: 10.1097/MOU.0000000000000551. No abstract available.

PMID:
30256260
47.

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.

Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB.

Eur Urol Focus. 2018 Jul;4(4):512-521. doi: 10.1016/j.euf.2018.08.019. Epub 2018 Sep 3.

PMID:
30190111
48.

New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ.

Bladder Cancer. 2018 Jul 30;4(3):339-342. doi: 10.3233/BLC-189032. No abstract available.

49.

Advances in risk stratification of bladder cancer to guide personalized medicine.

Matulay JT, Kamat AM.

F1000Res. 2018 Jul 25;7. pii: F1000 Faculty Rev-1137. doi: 10.12688/f1000research.14903.1. eCollection 2018. Review.

50.

Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer.

Fernández MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, Kiemeney LA, Malavaud B, Sanchez-Salas R, Soloway MS, Svatek RS, Vikram R, Vrieling A, Kamat AM.

World J Urol. 2019 Jan;37(1):3-13. doi: 10.1007/s00345-018-2436-y. Epub 2018 Aug 13. Review.

PMID:
30105454

Supplemental Content

Loading ...
Support Center